Selected research
Market Analysis & Forecast
Global Untargeted Metabolomics Market Analysis and Forecast 2026-2032
Market perspective
The global Untargeted Metabolomics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Untargeted Metabolomics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Untargeted Metabolomics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Untargeted Metabolomics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Untargeted Metabolomics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Untargeted Metabolomics include Creative Proteomics, Metabolon, Alfa Chemistry, Novelgene Technologies, MtoZ-Biolabs Inc., CD Genomics, Metware Biotechnology Inc (Metware), BGI Genomics and APPLIED PROTEIN TECHNOLOGY, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Untargeted Metabolomics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Untargeted Metabolomics, also provides the revenue of main regions and countries. Of the upcoming market potential for Untargeted Metabolomics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Untargeted Metabolomics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Untargeted Metabolomics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Untargeted Metabolomics revenue, projected growth trends, production technology, application and end-user industry.
Untargeted Metabolomics Segment by Company
Creative Proteomics
Metabolon
Alfa Chemistry
Novelgene Technologies
MtoZ-Biolabs Inc.
CD Genomics
Metware Biotechnology Inc (Metware)
BGI Genomics
APPLIED PROTEIN TECHNOLOGY
Suzhou PANOMIX Biomedical Tech Co.,Ltd
OBiO Technology ( Shanghai ) Corp.,Ltd.
Beijing Huayi innovation & BioTechnology Co., Ltd
Abace Biotechnology
Metabo-Profile
Untargeted Metabolomics Segment by Type
Plant Untargeted Metabolomics
Human Untargeted Metabolomics
Other
Untargeted Metabolomics Segment by Application
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Untargeted Metabolomics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Untargeted Metabolomics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Untargeted Metabolomics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Untargeted Metabolomics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Untargeted Metabolomics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Untargeted Metabolomics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Untargeted Metabolomics revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Plant Untargeted Metabolomics
- Human Untargeted Metabolomics
- Other
Applications
- Academic and Research Institutions
- Pharmaceutical and Biotechnology Companies
Companies covered
- Creative Proteomics
- Metabolon
- Alfa Chemistry
- Novelgene Technologies
- MtoZ-Biolabs Inc.
- CD Genomics
- Metware Biotechnology Inc (Metware)
- BGI Genomics
- APPLIED PROTEIN TECHNOLOGY
- Suzhou PANOMIX Biomedical Tech Co.,Ltd
- OBiO Technology ( Shanghai ) Corp.,Ltd.
- Beijing Huayi innovation & BioTechnology Co., Ltd
- Abace Biotechnology
- Metabo-Profile
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Untargeted Metabolomics Market by Type
- 1.2.1 Global Untargeted Metabolomics Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Plant Untargeted Metabolomics
- 1.2.3 Human Untargeted Metabolomics
- 1.2.4 Other
- 1.3 Untargeted Metabolomics Market by Application
- 1.3.1 Global Untargeted Metabolomics Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Academic and Research Institutions
- 1.3.3 Pharmaceutical and Biotechnology Companies
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Untargeted Metabolomics Market Dynamics
- 2.1 Untargeted Metabolomics Industry Trends
- 2.2 Untargeted Metabolomics Industry Drivers
- 2.3 Untargeted Metabolomics Industry Opportunities and Challenges
- 2.4 Untargeted Metabolomics Industry Restraints
3 Global Growth Perspective
- 3.1 Global Untargeted Metabolomics Market Perspective (2021-2032)
- 3.2 Global Untargeted Metabolomics Growth Trends by Region
- 3.2.1 Global Untargeted Metabolomics Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Untargeted Metabolomics Market Size by Region (2021-2026)
- 3.2.3 Global Untargeted Metabolomics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Untargeted Metabolomics Revenue by Players
- 4.1.1 Global Untargeted Metabolomics Revenue by Players (2021-2026)
- 4.1.2 Global Untargeted Metabolomics Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Untargeted Metabolomics Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Untargeted Metabolomics Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Untargeted Metabolomics Key Players Headquarters & Area Served
- 4.4 Global Untargeted Metabolomics Players, Product Type & Application
- 4.5 Global Untargeted Metabolomics Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Untargeted Metabolomics Market CR5 and HHI
- 4.6.3 2025 Untargeted Metabolomics Tier 1, Tier 2, and Tier 3
5 Untargeted Metabolomics Market Size by Type
- 5.1 Global Untargeted Metabolomics Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Untargeted Metabolomics Revenue by Type (2021-2032)
- 5.3 Global Untargeted Metabolomics Revenue Market Share by Type (2021-2032)
6 Untargeted Metabolomics Market Size by Application
- 6.1 Global Untargeted Metabolomics Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Untargeted Metabolomics Revenue by Application (2021-2032)
- 6.3 Global Untargeted Metabolomics Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Creative Proteomics
- 7.1.1 Creative Proteomics Company Information
- 7.1.2 Creative Proteomics Business Overview
- 7.1.3 Creative Proteomics Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.1.4 Creative Proteomics Untargeted Metabolomics Product Portfolio
- 7.1.5 Creative Proteomics Recent Developments
- 7.2 Metabolon
- 7.2.1 Metabolon Company Information
- 7.2.2 Metabolon Business Overview
- 7.2.3 Metabolon Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.2.4 Metabolon Untargeted Metabolomics Product Portfolio
- 7.2.5 Metabolon Recent Developments
- 7.3 Alfa Chemistry
- 7.3.1 Alfa Chemistry Company Information
- 7.3.2 Alfa Chemistry Business Overview
- 7.3.3 Alfa Chemistry Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.3.4 Alfa Chemistry Untargeted Metabolomics Product Portfolio
- 7.3.5 Alfa Chemistry Recent Developments
- 7.4 Novelgene Technologies
- 7.4.1 Novelgene Technologies Company Information
- 7.4.2 Novelgene Technologies Business Overview
- 7.4.3 Novelgene Technologies Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.4.4 Novelgene Technologies Untargeted Metabolomics Product Portfolio
- 7.4.5 Novelgene Technologies Recent Developments
- 7.5 MtoZ-Biolabs Inc.
- 7.5.1 MtoZ-Biolabs Inc. Company Information
- 7.5.2 MtoZ-Biolabs Inc. Business Overview
- 7.5.3 MtoZ-Biolabs Inc. Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.5.4 MtoZ-Biolabs Inc. Untargeted Metabolomics Product Portfolio
- 7.5.5 MtoZ-Biolabs Inc. Recent Developments
- 7.6 CD Genomics
- 7.6.1 CD Genomics Company Information
- 7.6.2 CD Genomics Business Overview
- 7.6.3 CD Genomics Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.6.4 CD Genomics Untargeted Metabolomics Product Portfolio
- 7.6.5 CD Genomics Recent Developments
- 7.7 Metware Biotechnology Inc (Metware)
- 7.7.1 Metware Biotechnology Inc (Metware) Company Information
- 7.7.2 Metware Biotechnology Inc (Metware) Business Overview
- 7.7.3 Metware Biotechnology Inc (Metware) Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.7.4 Metware Biotechnology Inc (Metware) Untargeted Metabolomics Product Portfolio
- 7.7.5 Metware Biotechnology Inc (Metware) Recent Developments
- 7.8 BGI Genomics
- 7.8.1 BGI Genomics Company Information
- 7.8.2 BGI Genomics Business Overview
- 7.8.3 BGI Genomics Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.8.4 BGI Genomics Untargeted Metabolomics Product Portfolio
- 7.8.5 BGI Genomics Recent Developments
- 7.9 APPLIED PROTEIN TECHNOLOGY
- 7.9.1 APPLIED PROTEIN TECHNOLOGY Company Information
- 7.9.2 APPLIED PROTEIN TECHNOLOGY Business Overview
- 7.9.3 APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.9.4 APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Product Portfolio
- 7.9.5 APPLIED PROTEIN TECHNOLOGY Recent Developments
- 7.10 Suzhou PANOMIX Biomedical Tech Co.,Ltd
- 7.10.1 Suzhou PANOMIX Biomedical Tech Co.,Ltd Company Information
- 7.10.2 Suzhou PANOMIX Biomedical Tech Co.,Ltd Business Overview
- 7.10.3 Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.10.4 Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Product Portfolio
- 7.10.5 Suzhou PANOMIX Biomedical Tech Co.,Ltd Recent Developments
- 7.11 OBiO Technology ( Shanghai ) Corp.,Ltd.
- 7.11.1 OBiO Technology ( Shanghai ) Corp.,Ltd. Company Information
- 7.11.2 OBiO Technology ( Shanghai ) Corp.,Ltd. Business Overview
- 7.11.3 OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.11.4 OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Product Portfolio
- 7.11.5 OBiO Technology ( Shanghai ) Corp.,Ltd. Recent Developments
- 7.12 Beijing Huayi innovation & BioTechnology Co., Ltd
- 7.12.1 Beijing Huayi innovation & BioTechnology Co., Ltd Company Information
- 7.12.2 Beijing Huayi innovation & BioTechnology Co., Ltd Business Overview
- 7.12.3 Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.12.4 Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Product Portfolio
- 7.12.5 Beijing Huayi innovation & BioTechnology Co., Ltd Recent Developments
- 7.13 Abace Biotechnology
- 7.13.1 Abace Biotechnology Company Information
- 7.13.2 Abace Biotechnology Business Overview
- 7.13.3 Abace Biotechnology Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.13.4 Abace Biotechnology Untargeted Metabolomics Product Portfolio
- 7.13.5 Abace Biotechnology Recent Developments
- 7.14 Metabo-Profile
- 7.14.1 Metabo-Profile Company Information
- 7.14.2 Metabo-Profile Business Overview
- 7.14.3 Metabo-Profile Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
- 7.14.4 Metabo-Profile Untargeted Metabolomics Product Portfolio
- 7.14.5 Metabo-Profile Recent Developments
8 North America
- 8.1 North America Untargeted Metabolomics Revenue (2021-2032)
- 8.2 North America Untargeted Metabolomics Revenue by Type (2021-2032)
- 8.2.1 North America Untargeted Metabolomics Revenue by Type (2021-2026)
- 8.2.2 North America Untargeted Metabolomics Revenue by Type (2027-2032)
- 8.3 North America Untargeted Metabolomics Revenue Share by Type (2021-2032)
- 8.4 North America Untargeted Metabolomics Revenue by Application (2021-2032)
- 8.4.1 North America Untargeted Metabolomics Revenue by Application (2021-2026)
- 8.4.2 North America Untargeted Metabolomics Revenue by Application (2027-2032)
- 8.5 North America Untargeted Metabolomics Revenue Share by Application (2021-2032)
- 8.6 North America Untargeted Metabolomics Revenue by Country
- 8.6.1 North America Untargeted Metabolomics Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Untargeted Metabolomics Revenue by Country (2021-2026)
- 8.6.3 North America Untargeted Metabolomics Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Untargeted Metabolomics Revenue (2021-2032)
- 9.2 Europe Untargeted Metabolomics Revenue by Type (2021-2032)
- 9.2.1 Europe Untargeted Metabolomics Revenue by Type (2021-2026)
- 9.2.2 Europe Untargeted Metabolomics Revenue by Type (2027-2032)
- 9.3 Europe Untargeted Metabolomics Revenue Share by Type (2021-2032)
- 9.4 Europe Untargeted Metabolomics Revenue by Application (2021-2032)
- 9.4.1 Europe Untargeted Metabolomics Revenue by Application (2021-2026)
- 9.4.2 Europe Untargeted Metabolomics Revenue by Application (2027-2032)
- 9.5 Europe Untargeted Metabolomics Revenue Share by Application (2021-2032)
- 9.6 Europe Untargeted Metabolomics Revenue by Country
- 9.6.1 Europe Untargeted Metabolomics Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Untargeted Metabolomics Revenue by Country (2021-2026)
- 9.6.3 Europe Untargeted Metabolomics Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Untargeted Metabolomics Revenue (2021-2032)
- 10.2 China Untargeted Metabolomics Revenue by Type (2021-2032)
- 10.2.1 China Untargeted Metabolomics Revenue by Type (2021-2026)
- 10.2.2 China Untargeted Metabolomics Revenue by Type (2027-2032)
- 10.3 China Untargeted Metabolomics Revenue Share by Type (2021-2032)
- 10.4 China Untargeted Metabolomics Revenue by Application (2021-2032)
- 10.4.1 China Untargeted Metabolomics Revenue by Application (2021-2026)
- 10.4.2 China Untargeted Metabolomics Revenue by Application (2027-2032)
- 10.5 China Untargeted Metabolomics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Untargeted Metabolomics Revenue (2021-2032)
- 11.2 Asia Untargeted Metabolomics Revenue by Type (2021-2032)
- 11.2.1 Asia Untargeted Metabolomics Revenue by Type (2021-2026)
- 11.2.2 Asia Untargeted Metabolomics Revenue by Type (2027-2032)
- 11.3 Asia Untargeted Metabolomics Revenue Share by Type (2021-2032)
- 11.4 Asia Untargeted Metabolomics Revenue by Application (2021-2032)
- 11.4.1 Asia Untargeted Metabolomics Revenue by Application (2021-2026)
- 11.4.2 Asia Untargeted Metabolomics Revenue by Application (2027-2032)
- 11.5 Asia Untargeted Metabolomics Revenue Share by Application (2021-2032)
- 11.6 Asia Untargeted Metabolomics Revenue by Country
- 11.6.1 Asia Untargeted Metabolomics Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Untargeted Metabolomics Revenue by Country (2021-2026)
- 11.6.3 Asia Untargeted Metabolomics Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Untargeted Metabolomics Revenue (2021-2032)
- 12.2 SAMEA Untargeted Metabolomics Revenue by Type (2021-2032)
- 12.2.1 SAMEA Untargeted Metabolomics Revenue by Type (2021-2026)
- 12.2.2 SAMEA Untargeted Metabolomics Revenue by Type (2027-2032)
- 12.3 SAMEA Untargeted Metabolomics Revenue Share by Type (2021-2032)
- 12.4 SAMEA Untargeted Metabolomics Revenue by Application (2021-2032)
- 12.4.1 SAMEA Untargeted Metabolomics Revenue by Application (2021-2026)
- 12.4.2 SAMEA Untargeted Metabolomics Revenue by Application (2027-2032)
- 12.5 SAMEA Untargeted Metabolomics Revenue Share by Application (2021-2032)
- 12.6 SAMEA Untargeted Metabolomics Revenue by Country
- 12.6.1 SAMEA Untargeted Metabolomics Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Untargeted Metabolomics Revenue by Country (2021-2026)
- 12.6.3 SAMEA Untargeted Metabolomics Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst